Insulet Corp
GOV
Company Profile
Business description
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.
Contact
100 Nagog Park
ActonMA01720
USAT: +1 978 600-7000
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
3,900
Stocks News & Analysis
stocks
ASX healthcare giant remains well positioned despite share slump
We welcome the CEO change at CSL but relatively soft plasma performance will postpone recovery
stocks
Australian bank remains overvalued despite strong result
When strong fundamentals meet persistent valuation headwinds.
stocks
Chart of the Week: Soft earnings growth outlook for Australian banks
The latest take from our equity research analysts.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,312.10 | 11.00 | -0.12% |
| CAC 40 | 8,313.24 | 14.64 | -0.18% |
| DAX 40 | 24,856.15 | 131.70 | -0.53% |
| Dow JONES (US) | 50,121.40 | 66.74 | -0.13% |
| FTSE 100 | 10,472.11 | 118.27 | 1.14% |
| HKSE | 27,266.38 | 83.23 | 0.31% |
| NASDAQ | 23,066.47 | 36.01 | -0.16% |
| Nikkei 225 | 57,849.82 | 199.28 | 0.35% |
| NZX 50 Index | 13,537.14 | 29.86 | 0.22% |
| S&P 500 | 6,941.47 | 0.34 | -0.00% |
| S&P/ASX 200 | 9,069.20 | 7.20 | 0.08% |
| SSE Composite Index | 4,131.57 | 0.42 | -0.01% |